Significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin in network meta-analysis
Your search for apixaban returned 6 results
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban.
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.
Andexxa was granted accelerated approval by the FDA in May 2018.
Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.
Asundexian is an investigational oral Factor XIa inhibitor.